EcoDrugPlus

Chemokine (C-X-C Motif), Receptor 4b

Ensembl ID : ENSIPUG00000010000
Gene Symbol: CXCR4B
3 Cross references
201 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSIPUG00000002214
Gene Symbol: CCKAR
3 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSIPUG00000013725
Gene Symbol: CCKBRA
4 Cross references
253 Possible Orthologues:

Cholecystokinin Receptor

Ensembl ID : ENSIPUG00000000319
Gene Symbol: LOC108266130
3 Cross references
131 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSIPUG00000019568
Gene Symbol: LOC124626838
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSIPUG00000002079
Gene Symbol: CHRM1
1 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSIPUG00000004348
Gene Symbol: CHRM2
3 Cross references
185 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSIPUG00000014662
Gene Symbol: CHRM3
4 Cross references
187 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSIPUG00000010887
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSIPUG00000010961
Gene Symbol: CHRNB4
4 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSIPUG00000015809
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 3b

Ensembl ID : ENSIPUG00000004903
Gene Symbol: CHRM3B
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).